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Background: Endothelial lipase (EL) plays an important role in the regulation of lipid metabolism by reducing the
high density lipoprotein cholesterol (HDL-C) levels and inducing the macrophages to take up native low density
lipoprotein cholesterol (LDL-C). Our purpose was to investigate the impact of EL genetic polymorphisms on the
lipid-lowering effects of rosuvastatin in Chinese coronary artery disease (CAD) patients.
Methods: One hundred twenty-one unrelated CAD patients, who underwent the treatment with rosuvastatin
(10mg/day) for four to eight weeks, were enrolled in this study. Before and after treatment, serum lipids levels
were measured. Genotypes of EL 2037T/C and 2237 G/A polymorphisms were detected by polymerase chain
reaction-restriction fragment length polymorphism (PCR-RFLP) method.
Results: Patients with EL 2037C allele (CC + CT) had significantly lower LDL-C levels than those with TT genotype
(CC + CT: 2.60 ± 0.74 mmol/l; TT: 2.90 ± 0.87 mmol/l; P = 0.047), before rosuvastatin treatment. No significant differences
between baseline lipid levels and the EL 2237G/A genotypes were observed. After treatment with rosuvastatin,
total cholesterol (TC), high triglyceride (TG) and LDL-C levels decreased from baseline, on average, by 23.09 %
(4.59 ± 0.96 mmol/l to 3.47 ± 0.83 mmol/l), 6.36 % (2.01 ± 1.18 mmol/l to 1.68 ± 1.16 mmol/l), 32.48 % (2.77 ± 0.
83 mmol/l to 1.79 ± 0.62 mmol/l), respectively (all P < 0.05) in all patients. While changes in HDL-C levels did
not reach statistical significance. No significant effects of EL 2037T/C or 2237G/A polymorphism were observed
on lipid-lowering effects of rosuvastatin.
Conclusions: EL 2037T/C and 2237 G/A polymorphisms might not affect the lipid-owing effects of rosuvastatin
in Chinese CAD patients.
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Epidemiological data show that coronary artery disease
(CAD) will remain one of the leading causes of morbidity
and mortality up to 2030. About 7.3 million people world-
wide die from CAD annually, according to the report from
World Health Organization (WHO) [1].
Dyslipidemia, including high total cholesterol (TC),
high triglyceride (TG), high low density lipoprotein chol-
esterol (LDL-C), and/or low high density lipoprotein
cholesterol (HDL-C), is one of the important risk* Correspondence: cgj982@126.com
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CAD, it is most important to decrease the TC, TG and
LDL-C levels. Statin, which can reduce the LDL-C
levels and enhance the HDL-C levels, is the most im-
portant class of the lipid-lowering drugs to prevent and
treat CAD [4, 5].
Pharmacogenetic studies have revealed that single
nucleotide polymorphisms (SNPs) might influence the
lipid-lowering effects of statins [6]. The genetic difference
leads to the different lipid-lowering effects of statins in
individual patient [7–9]. The results from a meta-analysis
revealed that the ABCB1 C3435T polymorphism might be
associated with the lipid-lowering effects of statins in
patients with hypercholesterolemia. The LDL-C loweringle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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than those in patients with CC genotype [7]. Li J et al. [8]
concluded that the cholesterol ester transfer protein TaqIB
polymorphism affected the lipid-lowering effects of ator-
vastatin in CAD patients. After three months of treatment
with atorvastatin, the TG levels in B2B2 patients was
lower than that in B1 carriers (P = 0.009). However, Fu Q
et al. [10] found that the SLCO1B1 polymorphisms were
not associated with lipid-lowering effects of atorvastatin
and simvastatin in Chinese patients.
The endothelial lipase (EL), which was discovered by
Hirata et al. [11] in 1999, belongs to the lipase family.
Previous studies have revealed that the over-expression
of EL in human Apo-AI transgenic mice led to a large
reduction in the HDL-C levels. Compared with wild type
mice, the scavenger receptor class BI (SR-BI) and ATP-
binding cassette transporter A1 (ABCA1)-mediated choles-
terol efflux changed greatly in mice with over-expression of
EL [12]. It is well recognized that the serum EL concentra-
tion was closely associated with cholesterol levels, especially
HDL-C levels, in different populations, and the risk of
CAD [13]. In vivo, EL expression could be inhibited by sta-
tin via Toll-like receptors-4 [14]. The further studies found
EL gene polymorphisms might affect the serum cholesterol
levels, and was associated with the CAD risk [15–17].
However, it is not known whether EL polymorphisms
can affect the lipid-lowering effects of statins. Therefore, we
performed this study to determine the impact of EL
2037 T/C (rs3744843), 2237 G/A (rs3744841) genetic
polymorphisms on the lipid-lowering effects of rosuvastatin
in Chinese CAD patients.
Methods
Subjects
A total of 121 CAD patients (87 males and 34 females)
with or without hyperlipideamia, randomly selected from
our previous hospital based case-control study, were en-
rolled in the present study. All subjects were selected from
the Department of Cardiology of Wujin Hospital affiliated
to Jiangsu University between February 2009 and May
2015. Diagnosis of CAD was confirmed according to the
WHO criteria. All of the patients had coronary angiography
examination. Patients with thyroid disease (hyperthyroidism
or hypothyroidism), malignant disease, renal or hepatic
disease were excluded.
All patients entering this study were treated with 10mg
rosuvastatin daily for four to eight weeks. None of the pa-
tients underwent statin treatment for at least one month
before entry into this study or took any other lipid-
lowering drugs during this period. Before and after treat-
ment, the lipids levels were measured. When the LDL-C
levels decreased below 1.80 mmol/l or more than 50 %
compared with the baseline LDL-C levels, we seemed the
lipid-lowering treatment attaining the guideline levels. Toexplore the side effects of rosuvastatin, the alanine amino-
transferase (ALT) and creatine kinase (CK) levels were de-
tected after treatment.Detection of lipid profiles
After overnight fasting, blood was collected from each pa-
tient. Serum TC, TG, HDL-C and LDL-C were measured
by methods of oxidase. All of the biochemical indexes were
analyzed by automatic biochemical analyzer (Olympus
AU5400).Genotyping of EL polymorphisms
The procedure of genomic DNA extraction was according
to our previous method [18]. Briefly, the genomic DNA
was extracted from peripheral blood by standard phenol-
chloroform method and was stored at -70 °C until use.
Genotyping of the EL 2037 T/C and 2237 G/A polymor-
phisms were performed by polymerase chain reaction
(PCR) followed by restriction fragment length polymorph-
ism (RFLP) analysis. Amplification of the fragment was
performed by using the sense 5′-GTT ACT GCT GAG
GAC CCA C-3′ and the antisense 5′-TAG AAA TCC
CAA CTC CAC TG-3′ (which were synthesized by Takara
Biotechnology, Dalian, Co., Ltd.) for these two poly-
morphisms. The PCR reactive conditions were: de-
naturation for 5 min at 94 °C, followed by 35 cycles at
94 °C for 15 s, 58 °C for 30 s, 72 °C for 30s and 72 °C
for 10 min. The PCR product was digested with restric-
tion enzyme Sma I for 2037 T/C and BseD I for 2237
G/A at 55 °C overnight. The digested PCR product was
separated by 1.5 % agarose gel electrophoresis and visual-
ized under ultraviolet light. To confirm the genotyping re-
sults, a part of PCR products was sent for sequencing
(Genewiz, Suzhou, China).Statistical analysis
All statistical evaluations were analyzed by using SPSS
software (version 17.0, SPSS Inc., Chicago, Illinois,
USA). Comparison of continuous variables, which
were represented as means ± standard deviation (SD),
was performed by using independent-sample t-tests or
analysis of variance (ANOVA). Paired Student’s t test
was used for comparing the lipids differences before
and after rosuvastatin treatment. The genotype and
allele frequencies were counted directly. Qualitative
variables were reported as frequencies and percentages,
and evaluated by Chi-square test. The genotype distri-
bution for the Hardy-Weinberg equilibrium (HWE)
was also evaluated by Chi-square test. A P value less
than 0.05 (2-tailed) was considered as statistical
significance.
Fig. 1 Comparison of lipids levels before and after rosuvastatin
treatment in 121 patients with CAD. TC, total cholesterol; TG,
triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C,
low density lipoprotein cholesterol; Unit of TC, TG, HDL-C and
LDL-C is mmol/l; NS: no statistic; Data are shown as mean ± SD
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Baseline characteristics
The baseline clinical characteristics and lipid levels of
the present study are shown in Table 1. One hundred
twenty-one patients with CAD were enrolled in this
study. Of the 121 patients (age range: 39–82 years;
mean age: 62.17 ± 9.71 years), 87 (71.90 %) were males.
The percentages of smoking, essential hypertension and
diabetes mellitus were 34.71 %, 71.90 % and 24.79 %,
respectively.
Comparison of lipids levels before and after treatment
After treatment with rosuvastatin, TC, TG, and LDL-C
levels decreased from baseline, on average, by 23.09 %
(from 4.59 ± 0.96 mmol/l to 3.47 ± 0.83 mmol/l), 6.36 %
(from 2.01 ± 1.18 mmol/l to 1.68 ± 1.16mmol/l), 32.48 %
(from 2.77 ± 0.83 mmol/l to 1.79 ± 0.62 mmol/l), re-
spectively (all P < 0.05) in all patients (Fig. 1). How-
ever, changes in HDL-C levels did not reach statistical
significance (from 1.07 ± 0.30 mmol/l to 1.08 ± 0.26
mmol/l, P = 0.815).
The clinical characteristics of patients stratified by EL
genotypes
The frequency of the EL 2037 C variant allele was 24.38 %
in CAD patients, and the genotypic distribution was 4.96 %
(n = 6) for the CC genotype, 38.84 % (n = 47) for the CTTable 1 Clinical characteristics and lipids levels of patients before
treatment
Parameters n = 121
Age (years) 62.17 ± 9.71
Male [n(%)] 87 (71.90%)
Smoking [n(%)] 42 (34.71%)
EH [n(%)] 87 (71.90%)
DM [n(%)] 30 (24.79%)
TCa (mmol/l) 4.59 ± 0.96
TG (mmol/l) 2.01 ± 1.18
HDL-C (mmol/l) 1.07 ± 0.30
LDL-C (mmol/l) 2.77 ± 0.83
2037 T/C (rs3744843)
TT [n(%)] 68 (56.20%)
CT [n(%)] 47 (38.84%)
CC [n(%)] 6 (4.96%)
2237 G/A (rs3744841)
GG [n(%)] 46 (38.02%)
GA [n(%)] 60 (49.59%)
AA [n(%)] 15 (12.40%)
N number, EH essential hypertension, DM diabetes mellitus, TCa total
cholesterol, TG triglyceride, HDL-C high density lipoprotein cholesterol, LDL-C
low density lipoprotein cholesterol; Continuous variables were represented
as means ± SDgenotype, and 56.20 % (n = 68) for the TT genotype. For EL
2237 G/A, the frequencies of the GG, GA and AA geno-
types were 38.02, 49.59, and 12.40 %, respectively. The
genotypic distributions of these two polymorphisms were
both in accordance with HWE (for 2037 T/C, P = 0.35; for
2237 G/A, P = 0.50).
The baseline characteristics of patients stratified by EL
genotypes are shown in Table 2. For EL 2037 T/C, patients
with C allele (CC +CT) had significantly lower LDL-C
levels than those with TT homozygous genotype (CC +CT:
2.60 ± 0.74 mmol/l; TT: 2.90 ± 0.87 mmol/l; P = 0.047),
before rosuvastatin treatment. For EL 2237 G/A, no signifi-
cant differences in baseline lipid levels between the geno-
types were observed.Association between EL 2037 T/C and 2237 G/A
polymorphisms and the lipid-lowering effects of
rosuvastatin
For EL 2037 T/C polymorphism, TC and LDL-C levels
were significantly reduced in all the genotypes compared
with before treatment (Additional file 1: Table S1). How-
ever, the HDL-C levels did not change in any of the geno-
types. TG levels decreased significantly in subjects with
TT and TC genotypes.
For EL 2237G/A polymorphism, compared with the base-
line levels, TC, and LDL-C levels significantly decreased in
all of the genotypes. In addition, the TG levels decreased in
GA genotype (P < 0.001). Conversely, the concentration of
HDL-C did not change significantly in any of genotypes.
The effects of EL 2037 T/C and 2237 G/A polymorphism
on the lipid-lowering response to rosuvastatin are shown in
Figs. 2 and 3. The changes of lipids were presented as per-
centage. No significant effects of EL 2037T/C or 2237G/A
polymorphism were observed in lipid-lowering effects of
rosuvastatin.
Table 2 The baseline lipid profiles for EL 2037 T/C and 2237 G/A genotypes in CAD patients
SNPs N TCa (mmol/l) TG (mmol/l) HDL-C (mmol/l) LDL-C (mmol/l)
2037 T/C
TT 68 4.74 ± 1.00 1.98 ± 1.17 1.08 ± 0.25 2.90 ± 0.87
TC 47 4.47 ± 0.88 2.08 ± 1.27 1.09 ± 0.36 2.64 ± 0.74
CC 6 3.92 ± 0.85 1.91 ± 0.57 0.82 ± 0.18 2.32 ± 0.78
TC + CC 53 4.41 ± 0.89 2.06 ± 1.21 1.06 ± 0.36 2.60 ± 0.74*
2237 G/A
GG 46 4.63 ± 1.08 1.81 ± 0.95 1.04 ± 0.28 2.87 ± 0.93
GA 60 4.60 ± 0.85 2.21 ± 1.33 1.11 ± 0.33 2.69 ± 0.75
AA 15 4.45 ± 1.05 1.85 ± 1.16 1.03 ± 0.24 2.81 ± 0.80
GA + AA 75 4.57 ± 0.89 2.14 ± 1.30 1.09 ± 0.32 2.71 ± 0.76
SNPs single nucleotide polymorphisms, N number, TCa total cholesterol, TG triglyceride, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein
cholesterol
*P < 0.05 compared with TT group
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attaining the guideline LDL-C levels
In the present study, the percentage of patients attaining
the guideline LDL-C levels was 61.98 % (75/121). The
percentage in EL 2037 CC, CT, TT genotypes was 58.82 %
(40/68), 63.83 % (30/47) and 83.33 % (5/6), respectively. In
addition, the percentage in EL 2237 GG, GA, AA genotypes
was 52.17 % (24/46), 66.67 % (40/60) and 73.33 % (11/15),
respectively. No significant difference was found between
EL genetic polymorphisms and the percentage of patients
attaining the guideline LDL-C levels (for 2037 T/C: χ2 =
1.517, P = 0.468; for 2237 G/A: χ2 = 3.257, P = 0.196).
EL genetic polymorphisms and side effects of
rosuvastatin
After treatment with rosuvastatin, the alanine trans-
aminase (ALT) in three cases increased more than
three times of normal upper limit, which all occurred
in patients with heterozygous genotype (2037 TC andFig. 2 Comparison of percentage changes from baseline in lipid
levels among the EL 2037 T/C genotypes. TCΔ, total cholesterol; TG,
triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low
density lipoprotein cholesterol; Data are shown as mean ± standard error2237 GA genotype). Creatine kinase (CK) did not in-
crease significantly in any patient.
Discussion
To our knowledge, this is the first study to explore the
associations between EL polymorphisms and the lipid-
lowering effects of rosuvastatin in CAD patients. Our
present study revealed that EL 2037 T/C polymorphism
was associated with lipid levels, but EL 2037T/C and
2237 G/A polymorphisms did not influence the lipid-
lowering effects of rosuvastatin.
Because the view of cholesterol accumulative effect was
put forward, lipid-lowering therapy has been accepted as
the key preventive measure for atherosclerosis disease.
Thus, statins have been widely used clinically
Rosuvastatin, one of the competitive and selective inhibi-
tor of the HMG-CoA reductase, is widely used in the treat-
ment of CAD and hypercholesterolaemia [19]. Previous
studies have revealed that it can affect the lipids synthesisFig. 3 Comparison of percentage changes from baseline in lipid
levels among the EL 2237 G/A genotypes. TC, total cholesterol; TG,
triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low
density lipoprotein cholesterol; Data are shown as mean ± standard error
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therapeutic dose of statins is relatively small in Asians,
compared with Caucasian. In the present study, all CAD
patient accepted 10mg rosuvastatin therapy for four to
eight weeks. After treatment, the serum levels of TC, LDL-
C and TG all decreased significantly (P < 0.05). Although
the HDL-C levels also increased, it did not become statisti-
cally significant (1.07 ± 0.30 mmol/l vs.1.08 ± 0.26 mmol/l,
P = 0.653).
EL plays an important role in the regulation of lipid
metabolism, especially HDL-C, which was confirmed by
several studies. By reducing the HDL-C levels and inducing
the macrophages to take up native LDL-C, EL increases the
susceptibility of CAD. In recent years, Sun et al. revealed
that plasma EL activity was not only associated with plasma
HDL-C levels, but also the risk of CAD [13]. EL gene is
located on chromosome 18q21.1. In the past ten years,
several studies have investigated the effect of the EL gene
polymorphisms on lipid levels and found that EL polymor-
phisms were associated with lipids levels and the risk of
CAD in different populations. EL 2037T/C and 2237G/A
polymorphisms, which have been investigated by several
studies, are located in the coding region of the EL gene. In
2003, Yamakawa-Kobayashi K et al. [15] revealed that EL
2237G/A polymorphism was associated with HDL-C levels
in Japanese school-aged children. Carriers with AA geno-
type had lower HDL-C levels than those with GG or AA
genotypes. But no studies have been conducted to investi-
gate the relationship between the EL polymorphisms and
lipid-lowering effects of statins until now. Given the im-
portance of the EL polymorphisms in lipid metabolism, we
examined the association between the EL 2037 T/C and
2237 G/A polymorphisms and the lipid response to rosu-
vastatin in Chinese patients with CAD. We identified the
genotypic frequencies of EL 2037 T/C and 2237G/A poly-
morphisms in Chinese patients with CAD in this study. For
EL 2037T/C polymorphism, the frequencies of TT, TC, and
CC genotypes were 56.20, 38.84 and 4.96 % respectively.
For EL 2237 G/A polymorphism, the frequencies of the
GG, GA and AA genotypes were 38.02, 49.59, and 12.40 %,
respectively. The distributions of EL 2037 T/C and 2237 G/
A genotypes were not significantly different between
Chinese CAD patients and Japanese school-aged children.
In this study, we investigated the relationship between EL
polymorphisms and lipid levels. Because the number of pa-
tients with CC genotype was small, we combined the CC
and CT genotype as the C allele carrier (CC +CT). We
found that the carriers with 2037 C allele had lower LDL-C
levels than those with TT genotype (2.60 ± 0.74 mmol/l vs.
2.90 ± 0.87 mmol/l, P = 0.047). As for EL 2237 G/A poly-
morphism, no significant association was found between
genotypes and lipid levels.
In this study, 61.98 % patients attained the guideline
LDL-C levels after treatment with 10mg rosuvastatin.Whereas, no significant difference was found between
EL polymorphisms and the percentage of patients attain-
ing the guideline LDL-C levels.
Pharmacogenomic studies show that there is a consider-
able inter-individual variation in drug effects due to genetic
difference. Recently, the studies on the genes, which might
affect the lipid-lowering effects of statins, have mainly fo-
cused on metabolism enzymes, transporters and receptors
of drugs. In our study, we did not find any significant asso-
ciation between EL genotypes and the change of lipid levels
after treatment with rosuvastatin,. The negative results
might be due to the possibility that the polymorphisms or
expression of EL does not affect the metabolic enzyme and
the substrate of statins.
Pharmacogenomic studies also showed that SNPs might
affect the drug side effects, except the lipid-lowering effects
of statins. The main side effects of statins are liver damage
and myopathy. In our study, the ALT increased significantly
in three cases. All of them happened in patients with het-
erozygous genotypes. The CK did not increase significantly
in any patients. These suggested that the dosage of 10mg
rosuvastatin in Chinese population was safe.
Some limitations of this study should be considered
when we interpreted the results. Firstly, the major limita-
tion of this study is the small number of patients. Only
121 cases were enrolled in this study and thus the num-
bers of genotypes were relatively small, especially EL 2037
CC genotype (n = 6). Therefore, large sample and multi-
center studies are needed to confirm the results. Secondly,
all of the patients of this study were selected from CAD
population. The association between EL polymorphisms
and lipid-lowering effects of rosuvastatin was not inves-
tigated in non-CAD patients with hypercholesterolemia.
Our study might have the selection bias. Thirdly, the
present study was a retrospective cohort study and the ef-
ficiency was limited. Finally, the follow-up time in this
study was only four to eight weeks, and it is important to
know whether these polymorphisms influence the long-
term lipid-lowering effects of rosuvastatin.
Conclusion
The present results indicated that the EL gene poly-
morphism might not be a pharmacogenetic marker for
lipid-lowering therapy.
Additional files
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